Skip to main content
Top
Published in: Journal of Cachexia, Sarcopenia and Muscle 2/2014

01-06-2014 | Original Article

Early body weight loss during concurrent chemo-radiotherapy for non-small cell lung cancer

Authors: Céline M. H. Op den Kamp, Dirk K. M. De Ruysscher, Marieke van den Heuvel, Meike Elferink, Ruud M. A. Houben, Cary J. G. Oberije, Gerben P. Bootsma, Wiel H. Geraedts, Cordula C. M. Pitz, Ramon C. Langen, Emiel F. M. Wouters, Annemie M. W. J. Schols, Anne-Marie C. Dingemans

Published in: Journal of Cachexia, Sarcopenia and Muscle | Issue 2/2014

Login to get access

Abstract

Background and purpose

Radiation-esophagitis and weight loss are frequently observed toxicities in patients treated with concurrent chemo-radiotherapy (CT-RT) for non-small cell lung cancer (NSCLC) and might be related. The purpose was to investigate whether weight loss already starts early after initiation of CT-RT and precedes radiation-esophagitis.

Materials and methods

In a retrospective cohort, weight and esophagitis grade ≥2 were assessed during the first weeks of (CT-)RT in patients treated with concurrent (n = 102) or sequential (n = 92) therapy. In a prospective validation study, data on body weight, esophagitis grade ≥2, nutritional intake and muscle strength were obtained before, during and following CT-RT.

Results

In the retrospective cohort, early weight loss was observed in concurrently treated patients (p = 0.002), independent of esophagitis ≥ grade 2. Early weight loss was also observed in the prospective cohort (p = 0.003) and was not accompanied by decreases in nutritional intake. In addition lower limb muscle strength rapidly declined (p = 0.042). In the later weeks of treatment, further body weight loss occurred (p < 0.001) despite increased nutritional supplementation and body weight was only partly recovered after 4 weeks post CT-RT (p = 0.003).

Conclusions

Weight loss during concurrent CT-RT for NSCLC starts early and prior to onset of esophagitis, requiring timely and intense nutritional rehabilitation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol;28:2181-2190. Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol;28:2181-2190.
2.
go back to reference Cermak NM, Res PT, de Groot LC, van Saris WH, Loon LJ. Protein supplementation augments the adaptive response of skeletal muscle to resistance-type exercise training: a meta-analysis. Am J Clin Nutr. 2012;96:1454–64.PubMedCrossRef Cermak NM, Res PT, de Groot LC, van Saris WH, Loon LJ. Protein supplementation augments the adaptive response of skeletal muscle to resistance-type exercise training: a meta-analysis. Am J Clin Nutr. 2012;96:1454–64.PubMedCrossRef
3.
go back to reference Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245–51.PubMedCrossRef Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245–51.PubMedCrossRef
4.
go back to reference Pfister DG SAL, Weinstein GS, Mendenhall WM, Adelstein DJ, Ang KK, Clayman GL, Fisher SG, Forastiere AA, Harrison LB, Lefebvre J-L, Leupold N, List MA, O’Malley BO, Patel S, Marshall RP, Schwartz MA, and Wolf GT. American Society of Clinical Oncology Clinical Practice Guideline for the Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer. J Clin Oncol. 2006;24:3693–704. Pfister DG SAL, Weinstein GS, Mendenhall WM, Adelstein DJ, Ang KK, Clayman GL, Fisher SG, Forastiere AA, Harrison LB, Lefebvre J-L, Leupold N, List MA, O’Malley BO, Patel S, Marshall RP, Schwartz MA, and Wolf GT. American Society of Clinical Oncology Clinical Practice Guideline for the Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer. J Clin Oncol. 2006;24:3693–704.
5.
go back to reference De Ruysscher D, Botterweck A, Dirx M, et al. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann Oncol. 2009;20:98–102.PubMedCrossRef De Ruysscher D, Botterweck A, Dirx M, et al. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann Oncol. 2009;20:98–102.PubMedCrossRef
6.
go back to reference De Ruysscher D, Dehing C, Bremer RH, et al. Maximal neutropenia during chemotherapy and radiotherapy is significantly associated with the development of acute radiation-induced dysphagia in lung cancer patients. Ann Oncol. 2007;18:909–16.PubMedCrossRef De Ruysscher D, Dehing C, Bremer RH, et al. Maximal neutropenia during chemotherapy and radiotherapy is significantly associated with the development of acute radiation-induced dysphagia in lung cancer patients. Ann Oncol. 2007;18:909–16.PubMedCrossRef
7.
go back to reference De Ruysscher D, Faivre-Finn C, Nestle U, et al. European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer. J Clin Oncol. 2010;28:5301–10.PubMedCrossRef De Ruysscher D, Faivre-Finn C, Nestle U, et al. European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer. J Clin Oncol. 2010;28:5301–10.PubMedCrossRef
8.
go back to reference Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489–95.PubMedCrossRef Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489–95.PubMedCrossRef
9.
go back to reference Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d’Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol. 2005;23:5910–7.PubMedCrossRef Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d’Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol. 2005;23:5910–7.PubMedCrossRef
10.
go back to reference Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17:2692–9.PubMed Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17:2692–9.PubMed
11.
go back to reference Jain AK, Hughes RS, Sandler AB, et al. A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC). J Thorac Oncol. 2009;4:722–7.PubMedCrossRef Jain AK, Hughes RS, Sandler AB, et al. A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC). J Thorac Oncol. 2009;4:722–7.PubMedCrossRef
12.
go back to reference Johnke RM, Edwards JM, Evans MJ, et al. Circulating cytokine levels in prostate cancer patients undergoing radiation therapy: influence of neoadjuvant total androgen suppression. In Vivo. 2009;23:827–33.PubMed Johnke RM, Edwards JM, Evans MJ, et al. Circulating cytokine levels in prostate cancer patients undergoing radiation therapy: influence of neoadjuvant total androgen suppression. In Vivo. 2009;23:827–33.PubMed
13.
go back to reference McRackan TR, Watkins JM, Herrin AE, et al. Effect of body mass index on chemoradiation outcomes in head and neck cancer. Laryngoscope. 2008;118:1180–5.PubMedCrossRef McRackan TR, Watkins JM, Herrin AE, et al. Effect of body mass index on chemoradiation outcomes in head and neck cancer. Laryngoscope. 2008;118:1180–5.PubMedCrossRef
14.
go back to reference Ohno T, Kato S, Wakatsuki M, et al. Incidence and temporal pattern of anorexia, diarrhea, weight loss, and leukopenia in patients with cervical cancer treated with concurrent radiation therapy and weekly cisplatin: comparison with radiation therapy alone. Gynecol Oncol. 2006;103:94–9.PubMedCrossRef Ohno T, Kato S, Wakatsuki M, et al. Incidence and temporal pattern of anorexia, diarrhea, weight loss, and leukopenia in patients with cervical cancer treated with concurrent radiation therapy and weekly cisplatin: comparison with radiation therapy alone. Gynecol Oncol. 2006;103:94–9.PubMedCrossRef
15.
go back to reference Op den Kamp CM, Langen RC, Schols AM HA. Muscle atrophy in cachexia: can dietary protein tip the balance? Curr Opin Clin Nutr Metab Care. 2009;12:611–6.CrossRef Op den Kamp CM, Langen RC, Schols AM HA. Muscle atrophy in cachexia: can dietary protein tip the balance? Curr Opin Clin Nutr Metab Care. 2009;12:611–6.CrossRef
16.
go back to reference Op den Kamp CM, Langen RC, Snepvangers FJ, et al. Nuclear transcription factor kappaB activation and protein turnover adaptations in skeletal muscle of patients with progressive stages of lung cancer cachexia. Am J Clin Nutr 2013. Op den Kamp CM, Langen RC, Snepvangers FJ, et al. Nuclear transcription factor kappaB activation and protein turnover adaptations in skeletal muscle of patients with progressive stages of lung cancer cachexia. Am J Clin Nutr 2013.
17.
go back to reference Price KA, Azzoli CG, Gaspar LE. Chemoradiation for unresectable stage III non-small cell lung cancer. Semin Thorac Cardiovasc Surg. 2008;20:204–9.PubMedCrossRef Price KA, Azzoli CG, Gaspar LE. Chemoradiation for unresectable stage III non-small cell lung cancer. Semin Thorac Cardiovasc Surg. 2008;20:204–9.PubMedCrossRef
18.
go back to reference Rowell NP, O’Rourke N P. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2004:CD002140. Rowell NP, O’Rourke N P. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2004:CD002140.
19.
go back to reference Silver HJ, Dietrich MS, Murphy BA. Changes in body mass, energy balance, physical function, and inflammatory state in patients with locally advanced head and neck cancer treated with concurrent chemoradiation after low-dose induction chemotherapy. Head Neck. 2007;29:893–900.PubMedCrossRef Silver HJ, Dietrich MS, Murphy BA. Changes in body mass, energy balance, physical function, and inflammatory state in patients with locally advanced head and neck cancer treated with concurrent chemoradiation after low-dose induction chemotherapy. Head Neck. 2007;29:893–900.PubMedCrossRef
20.
go back to reference Tan BH, Fearon KC. Cachexia: prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care. 2008;11:400–7.PubMedCrossRef Tan BH, Fearon KC. Cachexia: prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care. 2008;11:400–7.PubMedCrossRef
22.
go back to reference van Baardwijk A, Wanders S, Boersma L, et al. Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer. J Clin Oncol;28:1380-1386. van Baardwijk A, Wanders S, Boersma L, et al. Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer. J Clin Oncol;28:1380-1386.
23.
go back to reference Vary TC, Lynch CJ. Nutrient signaling components controlling protein synthesis in striated muscle. J Nutr. 2007;137:1835–43.PubMed Vary TC, Lynch CJ. Nutrient signaling components controlling protein synthesis in striated muscle. J Nutr. 2007;137:1835–43.PubMed
25.
go back to reference Wolfe RR, Miller SL, Miller KB. Optimal protein intake in the elderly. Clin Nutr. 2008;27:675–84.PubMedCrossRef Wolfe RR, Miller SL, Miller KB. Optimal protein intake in the elderly. Clin Nutr. 2008;27:675–84.PubMedCrossRef
Metadata
Title
Early body weight loss during concurrent chemo-radiotherapy for non-small cell lung cancer
Authors
Céline M. H. Op den Kamp
Dirk K. M. De Ruysscher
Marieke van den Heuvel
Meike Elferink
Ruud M. A. Houben
Cary J. G. Oberije
Gerben P. Bootsma
Wiel H. Geraedts
Cordula C. M. Pitz
Ramon C. Langen
Emiel F. M. Wouters
Annemie M. W. J. Schols
Anne-Marie C. Dingemans
Publication date
01-06-2014
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cachexia, Sarcopenia and Muscle / Issue 2/2014
Print ISSN: 2190-5991
Electronic ISSN: 2190-6009
DOI
https://doi.org/10.1007/s13539-013-0127-5

Other articles of this Issue 2/2014

Journal of Cachexia, Sarcopenia and Muscle 2/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.